Advanced antisense oligonucleotide technology for exon skipping in Duchenne muscular dystrophy

A new generation of molecular drugs, never before tested in humans, will be given to nine boys with Duchenne muscular dystrophy to see if they can repair the faulty gene in both skeletal and heart muscle. Duchenne muscular dystrophy affects 1 in every 3500 live male births, or 250,000 people worldwide. Current antisense oligonucleotide drugs act like temporary molecular patches on the mutated DMD gene, restoring some dystrophin protein to skeletal muscle. But they require repeated doses and cannot reach the heart muscle efficiently—a critical gap, since heart failure is a leading cause of death in these patients. If successful, this trial could transform treatment for Duchenne by delivering the repair drug to the heart for the first time, potentially slowing or preventing cardiac decline alongside improvements in limb and breathing muscles. The MDEX Consortium, a UK-based group of preclinical scientists and clinicians, will first complete safety studies before administering the optimised drug to nine patients. This is an early-stage clinical test of a fundamentally new chemistry, not a proven therapy—but it directly addresses the heart-targeting problem that has limited all previous exon-skipping approaches.